NASDAQ:TMCI - Nasdaq - US89455T1097 - Common Stock - Currency: USD
6.26
-0.18 (-2.8%)
The current stock price of TMCI is 6.26 USD. In the past month the price decreased by -27.96%. In the past year, price decreased by -39.81%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.56 | 228.46B | ||
ISRG | INTUITIVE SURGICAL INC | 65.31 | 171.52B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.87 | 140.59B | ||
SYK | STRYKER CORP | 28.56 | 132.87B | ||
MDT | MEDTRONIC PLC | 15.61 | 106.93B | ||
BDX | BECTON DICKINSON AND CO | 14.37 | 57.39B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.95 | 41.51B | ||
IDXX | IDEXX LABORATORIES INC | 37.47 | 34.17B | ||
RMD | RESMED INC | 24.22 | 31.44B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 13.73 | 28.23B | ||
DXCM | DEXCOM INC | 40.2 | 26.01B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.38 | 22.69B |
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The firm is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The firm sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
TREACE MEDICAL CONCEPTS INC
100 Palmetto Park Place
Ponte Vedra FLORIDA 32081 US
CEO: John T. Treace
Employees: 516
Company Website: https://www.treace.com/
Investor Relations: https://investors.treace.com
Phone: 19043735940
The current stock price of TMCI is 6.26 USD. The price decreased by -2.8% in the last trading session.
The exchange symbol of TREACE MEDICAL CONCEPTS INC is TMCI and it is listed on the Nasdaq exchange.
TMCI stock is listed on the Nasdaq exchange.
13 analysts have analysed TMCI and the average price target is 11.73 USD. This implies a price increase of 87.38% is expected in the next year compared to the current price of 6.26. Check the TREACE MEDICAL CONCEPTS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TREACE MEDICAL CONCEPTS INC (TMCI) has a market capitalization of 393.69M USD. This makes TMCI a Small Cap stock.
TREACE MEDICAL CONCEPTS INC (TMCI) currently has 516 employees.
TREACE MEDICAL CONCEPTS INC (TMCI) has a support level at 5.03 and a resistance level at 7.46. Check the full technical report for a detailed analysis of TMCI support and resistance levels.
The Revenue of TREACE MEDICAL CONCEPTS INC (TMCI) is expected to grow by 9.5% in the next year. Check the estimates tab for more information on the TMCI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TMCI does not pay a dividend.
TREACE MEDICAL CONCEPTS INC (TMCI) will report earnings on 2025-05-13, after the market close.
TREACE MEDICAL CONCEPTS INC (TMCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
The outstanding short interest for TREACE MEDICAL CONCEPTS INC (TMCI) is 6.03% of its float. Check the ownership tab for more information on the TMCI short interest.
ChartMill assigns a fundamental rating of 3 / 10 to TMCI. While TMCI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TMCI reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -4.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.68% | ||
ROE | -49.38% | ||
Debt/Equity | 0.47 |
ChartMill assigns a Buy % Consensus number of 75% to TMCI. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -0.29% and a revenue growth 9.5% for TMCI